INTRODUCTION: Noninflammatory nodules may be persistent to dissolve. To evaluate the possible reasons, a case series of ultrasound images and medical data of patients who were prospectively referred with noninflammatory nodules were evaluated. MATERIALS AND METHODS: A total of 27 patients with nodules but without signs of inflammation were included. All cases were assessed with an 18-MHz linear ultrasound device. Exact location of the filler material was noted. Relations with clinical data were analyzed using chi-square tests. RESULTS: Early onset of complaints (2 weeks) in 11. All patients had multiple nodules. In all cases, the filler nodule was found to be located inside the fascia. Extension to the subcutaneous tissue was seen in 8 cases and to the deeper planes in 5. In 14 cases, the filler material was completely located inside layers of the fascia, and migration was observed in 5 cases. DISCUSSION: Accumulation of filler material in the superficial musculoaponeurotic system or fascia may be an important cause for the occurrence of persistent noninflammatory nodules, either by initial faulty injection technique or by later accumulation through the pathway generated with a needle or cannula. Ultrasound-guided injections are helpful to dissolve the nodule.
BACKGROUND: Hyaluronic acid–based dermal fillers are the cornerstones of wrinkle correction and facial contour redefinition. OBJECTIVE: To assess the efficacy and safety of ESTLF compared with RESL for the treatment of nasolabial folds (NLFs). MATERIALS AND METHODS: In this prospective, split-face, randomized, investigator and subject-blinded trial, 45 subjects with moderate-to-severe symmetrical NLFs were randomized to ESTLF on one side of the face and RESL on the other side and were followed up for 9 months. The primary end point was change in WSRS score from the baseline to Month 1 (M1). Secondary end points included changes in WSRS score at other time points, aesthetic improvement, wrinkle volume quantification, adverse events, and local tolerance. RESULTS: The efficacy difference between ESTLF and RESL at M1 was in favor of ESTLF (−0.16, CI, −0.28 to −0.03]), demonstrating its noninferiority. Considering other time points, significant differences were observed at 3 and 6 months for ESTLF, assessed with WSRS, GAIS, or NLF volume quantification. Both treatments were well tolerated. CONCLUSION: ESTLF is effective and well tolerated for the treatment of NLFs.
1 April 2017 in Annales de Dermatologie et de Vénéréologie
BACKGROUND: Previous ultrasound studies show that unanticipated filler spread can occur during injections. OBJECTIVE: This study investigates filler spread in common facial locations to determine its predictability based on specific anatomical layers. In particular, the authors focused on the direction of filler spread based on the patterns formed by the retinacula superficialis (RS) and retinacula profundus (RP). METHODS: In this observational study, the authors analyzed 440 filler treatments performed on 107 patients by a single injector (primary group) and 22 treatments by 4 additional injectors (reference group). Two filler types were evaluated: (1) 2 volumizing hyaluronic acid fillers and (2) 3 biostimulating fillers. The authors also assessed the feasibility of filler testing at the zygomatic arch. RESULTS: Distinct patterns of filler spread varied by injection site, consistent across both groups. The directional spread was predictable and influenced by the fibrous structures of the RS and RP. In addition, the lengths of the injected bolus varied significantly between the different fillers. CONCLUSION: In uncompromised tissue, filler spread is confined to the injected tissue layer, but follows directions dictated by the RS and RP fibers. While the overall direction of spread is unaffected by filler rheology, the injected length is influenced by the type of filler used.